Biogen Idec Stands Ready To Close Its $17.50 Per Share All
Biogen Idec Stands Ready to Close Its $17.50 Per Share All-Cash Tender Offer for Facet Biotech
Unless Facet stockholders tender a majority of the outstanding shares by the
Biogen Idec Stands Ready To Close Its $17.50 Per Share All

Facet Biotech Corporation (fact) Stock Quote | Thestreet.com
Get the latest FACT - Facet Biotech Corporation stock market performance data and financial news.
Facet Biotech Corporation (fact) Stock Quote | Thestreet.com

Edgar Pro
FACET BIOTECH PROVIDES 2009 FINANCIAL GUIDANCE AND LOWERS CASH UTILIZATION ESTIMATE — Company reports fourth quarter and full year 2008 financials that include results from
Edgar Pro

Biogen Idec Increases Offer To Acquire Facet Biotech To $17.50 Per
Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer
Biogen Idec Increases Offer To Acquire Facet Biotech To $17.50 Per

Fact Profile - Facet Biotech Corp Profile - Fact Company
Facet Biotech Corporation is a biotechnology company that develops oncology therapeutics.
Facet Biotech Corporation is a biotechnology company that develops
Fact Profile - Facet Biotech Corp Profile - Fact Company

Facet Biotech Q4 Net Loss Decreases | Tradingmarkets.com
TradingMarkets News for Facet Biotech Q4 net loss decreases
Facet Biotech Q4 Net Loss Decreases | Tradingmarkets.com

Facet Biotech Update And Analysis | Fusion Investing And Analysis
Facet Biotech has published a transcript of their conference call. There's some seemingly scripted questions by Robert Chapman that I found of interest.
Facet Biotech Update And Analysis | Fusion Investing And Analysis

Facet Biotech Corp: Information From Answers.com
(NASDAQ Global Market: FACT) Industry : Biotechnology On the web : n/a Employees : 327 Facet Biotech Corporation is a biotechnology company that develops oncology therapeutics
Facet Biotech Corp: Information From Answers.com

Facet Biotech Corp: Information From Answers.com
Facet Biotech Corp (NASDAQ Global Market: FACT) Contact Information Facet Biotech Corp 1400 Seaport Boulevard n/a Redwood City, CA 94063 UNITED STATES
Facet Biotech Corp: Information From Answers.com

Facet Biotech Stockholders Reject Biogen Idec Tender Offer - Pmd
Facet Biotech is a biotechnology company dedicated to advancing its pipeline of
Facet Biotech's expressly disclaims any obligation or undertaking to
Facet Biotech Stockholders Reject Biogen Idec Tender Offer - Pmd

Facet Biotech Rises After Board Rejects Biogen Bid (update1
[bn:WBTKR=FACT:US] Facet Biotech Corp., [] maker of an experimental treatment for multiple sclerosis, rose more than 11 percent above a proposed bid from [bn:WBTKR=BIIB:US] Biogen
Facet Biotech Rises After Board Rejects Biogen Bid (update1

Facet Biotech Announces February 23 Webcast Of Full Year And
Facet Biotech Announces February 23 Webcast of Full Year and Fourth Quarter 2009
Facet Biotech is a biotechnology company dedicated to advancing its
Facet Biotech Announces February 23 Webcast Of Full Year And

Facet Biotech Reports Fourth Quarter And Full Year 2009
Facet Biotech Reports Fourth Quarter and Full Year 2009 Financial Results
Facet Biotech Corporation (NASDAQ: FACT) today reported financial results for the fourth
Facet Biotech Reports Fourth Quarter And Full Year 2009

Facet Biotech And Bristol-myers Squibb Report Promising Phase I/ii
REDWOOD CITY, CA and PRINCETON, NJ--(Marketwire - December 7, 2009) - Facet Biotech Corporation (NASDAQ: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that
Facet Biotech And Bristol-myers Squibb Report Promising Phase I/ii

Emerging Drug Developer: Facet Biotech - Fiercebiotech
Facet Biotech cuts the burn, adds a product When Facet Biotech spun out of PDL BioPharma at the end of last year, it took with it a collection of promising clinical-stage antibody
Emerging Drug Developer: Facet Biotech - Fiercebiotech

Biospace - Facet Biotech News, Search Jobs, Events
Facet Biotech Announces February 23 Webcast of Full Year and Fourth Quarter 2009 Financial Results Conference Call 2/12/2010 9:45:27 AM More
Biospace - Facet Biotech News, Search Jobs, Events

Biogen Prepared For Proxy Battle For Facet Biotech | Xconomy
Cambridge, MA-based Biogen Idec told investors today that it's willing to wage a proxy battle to take control of the board of Facet Biotech, which it has been
Biogen Prepared For Proxy Battle For Facet Biotech | Xconomy

Facet Biotech Stock Quote | Fact Company Stock Market Quotes | Kraft
Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016
Facet Biotech Stock Quote | Fact Company Stock Market Quotes | Kraft

I pre-moderate first-time commenters. Please review my comment policy before leaving a comment.

Name (required)

E-mail (required, never displayed)

URI

Spam protection: what is the sum of 3 + 18 ?

---

No Friends Yet :(
Be the First! Mail me at admin [doggy] blogcentral.info